Iodide I-123

Identification

Summary

Iodide I-123 is a radiopharmaceutical diagnostic agent used for the evaluation of the thyroid function and/or morphology.

Generic Name
Iodide I-123
DrugBank Accession Number
DB09420
Background

Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123.

Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 122.9061
Monoisotopic: 122.906146524
Chemical Formula
I
Synonyms
  • 123I−
  • I 123
  • I-123
  • Iodide ion i-123
  • Iodine 123
  • Iodine-123

Pharmacology

Indication

Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentThyroid cancer metastases••• •••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Sodium Iodide I-123 is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4).

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Iodine-123 decays by electron capture with a physical half-life of 13.2 hours

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Limit iodine intake. Consume a low iodine diet for two weeks before the administration of Iodide I-123.
  • Take on an empty stomach. Fasting before the use of I-123 for imaging of the thyroid may increase accuracy.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Sodium iodide I-12329UKX3A61641927-88-2FVAUCKIRQBBSSJ-VVUPZWBASA-M
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
I 123 MiniCapsule10 mCi/1OralAnazao Health Corporation2012-05-23Not applicableUS flag
Sodium IodideCapsule100 uCi/1OralAmersham Health Inc.2006-07-10Not applicableUS flag
Sodium IodideCapsule200 uCi/1OralAmersham Health Inc.2006-07-10Not applicableUS flag
Sodium Iodide I 123Capsule, gelatin coated400 uCi/1OralCardinal Health 418, Inc2003-01-022013-09-30US flag
Sodium Iodide I 123Capsule, gelatin coated200 uCi/1OralCardinal Health 418, Inc2003-01-02Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Sodium Iodide I 123Capsule, gelatin coated100 uCi/1OralMallinckrodt2007-04-112017-07-01US flag
Sodium Iodide I 123Capsule, gelatin coated100 uCi/1OralCurium US LLC2015-11-04Not applicableUS flag
Sodium Iodide I 123Capsule, gelatin coated200 uCi/1OralCurium US LLC2007-04-11Not applicableUS flag
Sodium Iodide I 123Capsule, gelatin coated200 uCi/1OralMallinckrodt2007-04-112017-07-01US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
I 123 MiniIodide I-123 (10 mCi/1)CapsuleOralAnazao Health Corporation2012-05-23Not applicableUS flag

Categories

ATC Codes
V09FX02 — Sodium iodide (123i)
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous halogens. These are inorganic non-metallic compounds in which the largest atom is a nobel gas.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Homogeneous halogens
Sub Class
Not Available
Direct Parent
Homogeneous halogens
Alternative Parents
Not Available
Substituents
Homogeneous halogen
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
98QPV8670C
CAS number
69239-56-1
InChI Key
XMBWDFGMSWQBCA-AHCXROLUSA-M
InChI
InChI=1S/HI/h1H/p-1/i1-4
IUPAC Name
(123I)iodide
SMILES
[123I-]

References

General References
Not Available
PubChem Compound
135300
PubChem Substance
347827850
ChemSpider
119193
RxNav
1361657
ChEMBL
CHEMBL1249
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Iodine-123
FDA label
Download (2.79 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Enrolling by InvitationDiagnosticDementia / Mild Cognitive Impairment (MCI) / Parkinsonism / Rapid Eye Movement Sleep Behavior Disorder1
2CompletedDiagnosticMelancholic Depression1
2, 3RecruitingDiagnosticMalignancy of Thyroid Nodules1
1TerminatedDiagnosticAlzheimer's Disease (AD)1
Not AvailableCompletedNot AvailableCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral10 mCi/1
Injection, solutionIntravenous37 MBQ/ML
CapsuleOral
Injection, solutionIntravenous
CapsuleOral100 uCi/1
CapsuleOral200 uCi/1
Capsule, gelatin coatedOral100 uCi/1
Capsule, gelatin coatedOral200 uCi/1
Capsule, gelatin coatedOral400 uCi/1
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.02Chemaxon
pKa (Strongest Acidic)-9Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity13.95 m3·mol-1Chemaxon
Polarizability5.07 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-116.501274
predicted
DeepCCS 1.0 (2019)
[M-H]-116.501274
predicted
DeepCCS 1.0 (2019)
[M+H]+118.39668
predicted
DeepCCS 1.0 (2019)
[M+H]+118.39668
predicted
DeepCCS 1.0 (2019)
[M+Na]+125.9139
predicted
DeepCCS 1.0 (2019)
[M+Na]+125.9139
predicted
DeepCCS 1.0 (2019)

Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 16:52